Overview In-Licensing Out-Licensing		At Hana, we are continuously looking to expand our clinical development programs, and are in a position where we are seeking partners to out-license all or portions of our compounds. Our current PRIMARY development focus is on our M+M strategy (Marqibo® and Menadione). Therefore, the remaining programs in our development portfolio (Alocrest™ and Brakiva™) are programs we would consider out-licensing if we were able to find the right home for these compounds. Additionally, we are very interested in advancing our products through development and onto the market as quickly as possible and in as many indications as possible. As a result, we could consider co-development prospects for any of our compounds if we felt it would give us the opportunity to expand the indications and/or get the product to market more rapidly with a higher probability of success. Out-Licensing Opportunities Alocrest™ (vinorelbine liposomes injection, OPTISOME™) A Novel Targeted Anti-Cancer Compound for Breast and Lung Cancer. Phase 1 clinical data demonstrate the value of Alocrest™ over conventional vinorelbine. More Details » ALOCREST FACT SHEET Brakiva™ (topotecan liposomes injection, OPTISOME™) A Novel Targeted Anti-Cancer Compound for Small-Cell Lung Cancer and Ovarian Cancer. Preclinical data demonstrate the value of Brakiva™ over conventional topotecan. More Details » BRAKIVA FACT SHEET Co-Development Opportunities Marqibo® (vincristine sulfate liposomes injection, OPTISOME™) A Novel Targeted Nanoparticle-encapsulated Anti-Cancer Compound currently for Acute Lymphoblastic Leukemia (ALL) and Melanoma. Marqibo® has a robust safety database (over 600 patients) and has been extensively evaluated in lymphoid blood cancers such as non-Hodgkin’s lymphoma (NHL) and ALL. Hana has ongoing (or planned) clinical trials which may enable an accelerated approval in 2 indications. Future clinical trial development possible in multiple indications including NHL and melanoma. More Details » MARQIBO FACT SHEET Menadione Topical Lotion - A Topical Compound for Skin Rash Associated with EGFR Inhibitors. Treatment with EGFR inhibitors such as Tarceva®, Erbitux® and Vectibix® are associated with an acne-form rash involving the face, neck and upper torso in approximately 75% patients. 50% of patients who manifest skin toxicity experience significant discomfort. This results in drug discontinuation or dose reduction in at least 10% and up to 30% of all subjects. Drug delivery is targeted to the normal location of the EGFR-containing skin cells at the dermal/epidermal junction without interfering with EGFR inhibition systemically at the level of the tumor. More Details » MENADIONE FACT SHEET Please direct Business Development inquiries to: Gradon Knotts, Vice President, Business Development Hana Biosciences, Inc. 7000 Shoreline Court, Suite 370 South San Francisco, CA 94080 Phone: 650-228-2769 Fax: 650-588-2787 e-mail: gradon.knotts@hanabiosciences.com
© 2010 Hana Biosciences. Web design by Global 1 Design.